8-KLeadership ChangesShareholder Matters

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (May 15, 2018)

Filed May 15, 2018For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 15, 2018, reporting on several key corporate governance and shareholder matters. The most significant development for investors is the election of Colleen F. Reitan as a new independent director to the Board, expanding its size to eleven members. Ms. Reitan's appointment, effective June 1, 2018, includes a standard compensation package for non-employee directors, comprising annual cash fees and stock options, aligning her interests with shareholders. This move indicates the company's continued focus on strengthening its board oversight. The filing also details the results of Alnylam's 2018 Annual Meeting of Stockholders held on May 10, 2018. Shareholders re-elected four Class II directors with substantial support and approved the company's 2018 Stock Incentive Plan. Additionally, advisory approval was given to executive compensation, and PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2018. These outcomes reflect general shareholder confidence in the company's leadership and financial oversight.

Key Highlights

  • 1Board Expansion: Colleen F. Reitan elected as a new independent director, increasing the Board size to eleven members, effective June 1, 2018.
  • 2Director Compensation: Ms. Reitan will receive $50,000 annually in cash and stock options, with initial options for 18,000 shares vesting over three years, aligning her incentives with shareholders.
  • 3Director Re-elections: Four Class II directors were re-elected at the 2018 Annual Meeting of Stockholders, each to serve until the 2021 annual meeting.
  • 4Stock Incentive Plan Approval: Shareholders approved the Company's 2018 Stock Incentive Plan.
  • 5Executive Compensation Advisory Vote: Shareholders provided advisory approval for the compensation of named executive officers.
  • 6Auditor Ratification: PricewaterhouseCoopers LLP ratified as the independent auditor for the fiscal year ending December 31, 2018.

Frequently Asked Questions

Colleen F. Reitan has been elected as a new independent director to Alnylam Pharmaceuticals' Board of Directors. Her appointment, effective June 1, 2018, expands the Board and is part of the company's ongoing governance practices. She will serve as a Class III director with a term expiring at the 2019 annual meeting.

As a non-employee director, Ms. Reitan will receive an annual cash fee of $50,000. Additionally, she will receive an initial stock option grant to purchase 18,000 shares of common stock, vesting annually over three years. Starting in 2019, she will be eligible for annual stock option awards, typically 9,000 shares, vesting one year from the grant date. The exercise price will be the fair market value at the time of grant. She will also be reimbursed for related expenses and enter into a standard indemnification agreement.

At the May 10, 2018 Annual Meeting, shareholders re-elected four Class II directors, approved the 2018 Stock Incentive Plan, provided advisory approval for executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2018. These votes indicate general shareholder support for the company's leadership and governance.

The vote on the compensation of the company's named executive officers was an advisory vote. The results show strong support, with approximately 86.7 million 'For' votes compared to about 0.7 million 'Against' votes, indicating minimal shareholder opposition to the executive compensation structure.